Cart
sales@molnova.com
Befotertinib
CAS No. 1835667-63-4
Befotertinib( D-0316 )
Catalog No. M28217 CAS No. 1835667-63-4
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 235 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 525 | In Stock |
|
| 50MG | 732 | In Stock |
|
| 100MG | 1004 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBefotertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsD-0316
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorCDK2|CDK5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1835667-63-4
-
Formula Weight567.61
-
Molecular FormulaC29H32F3N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (88.09 mM)
-
SMILESC=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ka?mierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214.
molnova catalog
related products
-
WAY-270360
WAY-270360 is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.
-
Poziotinib hydrochlo...
Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors.?It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.?
-
Varlitinib
Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM respectively. Phase 2.
